antibiotic-Assistance Publique - Hôpitaux de Paris-acute pyelonephritis

The term **antibiotic-Assistance Publique - Hôpitaux de Paris-acute pyelonephritis** refers to the antibiotic treatment regimens evaluated by Assistance Publique - Hôpitaux de Paris (AP-HP) in a multicenter, randomized equivalence trial (NCT00215709). The study focused on infants and children under three years of age presenting with their first episode of acute pyelonephritis caused by Gram-negative strains. The trial compared two specific third-generation cephalosporins: a 10-day course of oral **cefixime** versus a sequential regimen consisting of 4 days of intravenous **ceftriaxone** followed by 6 days of oral cefixime. Both agents are bactericidal antibiotics that function by binding to and inhibiting penicillin-binding proteins (PBPs), which are essential for bacterial cell wall synthesis. The primary objective of the study was to demonstrate that oral cefixime is as effective as sequential intravenous/oral therapy in preventing renal scarring, thereby potentially reducing the necessity for hospitalization in pediatric patients.

Brand names

SupraxRocephin

Other names

cefiximeceftriaxoneantibioticantibiotics